Key Takeaways
- Brent crude prices surged over 5% to approximately $76 per barrel after the U.S. military launched "powerful" strikes on Iranian military sites in response to attacks on commercial shipping in the Strait of Hormuz.
- Asian equity markets faced a sharp sell-off, with the KOSPI (.KS11) plunging 3.3% and the Nikkei 225 (.N225) dropping 1% as a global semiconductor rout deepened.
- Apple (AAPL) is reportedly testing memory chips from China’s CXMT for devices sold in the Chinese market, a move that wiped out over $20 billion in market value from South Korean chip giants Samsung and SK Hynix.
- AstraZeneca (AZN) secured a major licensing deal with Sino Biopharmaceutical (1177.HK) worth up to $1.9 billion for a respiratory drug candidate.
- South Korea launched 24-hour foreign exchange trading for the first time to modernize its financial markets, though officials warned of potential volatility during overnight sessions.
Middle East Tensions Escalate as U.S. Hits Iranian Targets
Geopolitical risks returned to the forefront of global markets on Wednesday as U.S. Central Command (CENTCOM) confirmed it had begun a series of "powerful strikes" against multiple military targets in southern Iran. The strikes followed reports of at least three commercial vessels, including a Qatari LNG tanker and a Saudi supertanker, being struck by drones or projectiles in the Strait of Hormuz.
Iranian state media reported numerous explosions on Qeshm Island, Kharg Island, and in the port city of Bandar Abbas. The escalation has severely imperiled a fragile 60-day truce reached last month, with Brent crude futures jumping more than 5% to trade near $76.39 per barrel. Market participants are now pricing in a significant "war premium" as concerns grow over a prolonged disruption to the world's most critical energy chokepoint.
Apple’s Pivot to Chinese Chips Rattles Semiconductor Sector
A report from the Financial Times indicating that Apple (AAPL) has begun testing memory chips from ChangXin Memory Technologies (CXMT) has sent shockwaves through the global semiconductor supply chain. Apple is reportedly seeking to diversify its suppliers to mitigate "unsustainable" memory price hikes from established leaders like Samsung Electronics (005930.KS) and SK Hynix (000660.KS).
The news triggered a massive sell-off in Asian tech stocks, with SK Hynix plunging as much as 15% and Samsung falling 9% in earlier sessions. Analysts suggest that Apple's interest in CXMT—despite the firm being on a U.S. military blacklist—signals a strategic shift to use Chinese vendors as leverage against South Korean and American chipmakers.
Asian Markets Slump; JGB Yields Edge Higher
Broad-based selling hit Asian bourses as investors reacted to both the Middle East conflict and the tech sector rout. The Nikkei 225 (.N225) slipped 1%, extending recent declines, while the S&P/ASX 200 (.AXJO) in Australia dropped 1% in early trade. In South Korea, the KOSPI (.KS11) retreated to 7,407.32, a 3.3% decline, prompting the finance ministry to announce enhanced monitoring of market volatility.
In fixed income, Japanese Government Bond (JGB) yields continued their upward trajectory. The 30-year JGB yield edged higher toward 4%, tracking recent declines in U.S. Treasurys. The rise comes despite reports that the Japanese government modified its "Basic Policy" draft to avoid the appearance of pressuring the Bank of Japan on interest rate hikes.
AstraZeneca Inks $1.9 Billion Deal with Sino Biopharma
In a significant pharmaceutical development, AstraZeneca (AZN) signed an exclusive licensing agreement with Sino Biopharmaceutical (1177.HK) for the development of TQC3721, a respiratory drug candidate. Under the terms, AstraZeneca will pay $200 million upfront, with potential milestone payments totaling up to $1.9 billion.
The deal grants AstraZeneca the rights to develop and commercialize the drug—a PDE3/4 inhibitor aimed at chronic obstructive pulmonary disease (COPD)—outside of China. This marks the second major out-licensing deal for Sino Biopharma this year, further validating the innovation capabilities of Chinese biotech firms on the global stage.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.